Drug intelligence / Profile preview

DWC202003

Development stage: Unknown
Lead developer: Daewoong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

DWC202003 is a code name for an investigational drug used as a reference drug in clinical studies evaluating the pharmacokinetics and safety of test drugs like DWJ1439 and DWJ1464 in healthy adult volunteers. It is administered orally as a single dose in crossover studies. The mechanism of action, therapeutic class, and primary indication are not publicly disclosed. Daewoong Pharmaceutical sponsors the development and clinical trials.

Beyond the preview

Go deeper on DWC202003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DWC202003.

Explore the full profile